Ignite Creation Date:
2025-12-24 @ 3:16 PM
Ignite Modification Date:
2025-12-24 @ 3:16 PM
Study NCT ID:
NCT03127592
Status:
TERMINATED
Last Update Posted:
2023-02-09
First Post:
2017-04-17
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction
Sponsor:
Apsen Farmaceutica S.A.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-10-05
Start Date Type:
ACTUAL
Primary Completion Date:
2022-07-26
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-07-26
Completion Date Type:
ACTUAL
First Submit Date:
2017-04-17
First Submit QC Date:
None
Study First Post Date:
2017-04-25
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-02-07
Last Update Post Date:
2023-02-09
Last Update Post Date Type:
ACTUAL